2012
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, Miesowicz F, Dhodapkar KM, Dhodapkar MV. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2012, 121: 423-430. PMID: 23100308, PMCID: PMC3548165, DOI: 10.1182/blood-2012-06-435503.Peer-Reviewed Original ResearchConceptsHuman iNKT cellsINKT cellsCombination therapyAntitumor T-cell immunitySerum soluble IL2 receptorMonocyte-derived dendritic cellsNatural killer T cellsBroad immune activationLow-dose lenalidomideSoluble IL2 receptorCycles of therapyHuman NKT cellsT cell immunityKiller T cellsInnate immune cellsInduction of eosinophiliaActivation of monocytesPrevention of cancerCycles of combinationAsymptomatic myelomaClinical myelomaMeasurable diseaseClinical regressionClinical responseNKT cells
2009
Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in Humans
Neparidze N, Dhodapkar MV. Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in Humans. Annals Of The New York Academy Of Sciences 2009, 1174: 61-67. PMID: 19769737, PMCID: PMC2782771, DOI: 10.1111/j.1749-6632.2009.04931.x.Peer-Reviewed Original ResearchConceptsNKT cellsT cellsAntitumor immunityType I NKT cellsType II NKT cellsNatural killer T cellsPresence of CD1dI NKT cellsKiller T cellsAdvanced myelomaNKT activationDendritic cellsImmune therapyAlpha-GalactosylceramideCancer patientsCD1d moleculesLipid antigensPreclinical studiesThalidomide analoguesCD1dDistinct subsetsAgonist ligandsPatientsCancerType I